Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants with Allergic Asthma

Next Previous
X
Search
Trial Profile

A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants with Allergic Asthma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Briquilimab (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms ETESIAN
  • Sponsors Jasper Therapeutics

    • Most Recent Events

    • 02 Dec 2024 According to a Jasper Therapeutics media release, first patient has been dosed in this trial.
    • 07 Nov 2024 According to a Jasper Therapeutics media release, more recently, the EU, have cleared Jasper's Clinical Trial Application (CTA) for a Phase 1b/2a asthma challenge study evaluating briquilimab in asthma. The trial is expected to have as many as 10 sites in Canada and the EU with a key objective of demonstrating proof-of-concept in asthma utilizing a therapeutic dose to inform future trials in the broader asthma population.
    • 07 Nov 2024 Status changed from not yet recruiting to recruiting, according to a Jasper Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top